JP4326944B2 - ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ - Google Patents

ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ Download PDF

Info

Publication number
JP4326944B2
JP4326944B2 JP2003514007A JP2003514007A JP4326944B2 JP 4326944 B2 JP4326944 B2 JP 4326944B2 JP 2003514007 A JP2003514007 A JP 2003514007A JP 2003514007 A JP2003514007 A JP 2003514007A JP 4326944 B2 JP4326944 B2 JP 4326944B2
Authority
JP
Japan
Prior art keywords
ntb
polypeptide
cells
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003514007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507648A5 (enExample
JP2005507648A (ja
Inventor
モレッタ，アレッサンドロ
ボッティーノ，クリスティーナ
ビアッソーニ，ロベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
University of Genoa
Original Assignee
Innate Pharma SA
University of Genoa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA, University of Genoa filed Critical Innate Pharma SA
Publication of JP2005507648A publication Critical patent/JP2005507648A/ja
Publication of JP2005507648A5 publication Critical patent/JP2005507648A5/ja
Application granted granted Critical
Publication of JP4326944B2 publication Critical patent/JP4326944B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2003514007A 2001-07-19 2002-07-17 ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ Expired - Fee Related JP4326944B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401946 2001-07-19
PCT/EP2002/007945 WO2003008449A1 (en) 2001-07-19 2002-07-17 Ntb-a, a surface molecule involved in natural killer cells activity

Publications (3)

Publication Number Publication Date
JP2005507648A JP2005507648A (ja) 2005-03-24
JP2005507648A5 JP2005507648A5 (enExample) 2006-01-05
JP4326944B2 true JP4326944B2 (ja) 2009-09-09

Family

ID=8182813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003514007A Expired - Fee Related JP4326944B2 (ja) 2001-07-19 2002-07-17 ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ

Country Status (8)

Country Link
US (2) US7138243B2 (enExample)
EP (1) EP1406928B1 (enExample)
JP (1) JP4326944B2 (enExample)
AT (1) ATE464320T1 (enExample)
AU (1) AU2002325333B2 (enExample)
CA (1) CA2454185A1 (enExample)
DE (1) DE60235985D1 (enExample)
WO (1) WO2003008449A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001986A (es) * 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
TW200823237A (en) * 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
WO2014100740A1 (en) * 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US10344073B2 (en) 2014-01-09 2019-07-09 Hadasit Medical Research Services And Development Ltd. Cell compositions and methods for cancer therapy
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
WO2019126736A1 (en) * 2017-12-21 2019-06-27 New York University Pd-1 related cancer therapy
JP7458318B2 (ja) 2018-02-12 2024-03-29 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
EP4163367A4 (en) * 2020-06-09 2024-06-26 Samsung Life Public Welfare Foundation GENETICALLY MANIPULATED CELL STRAIN FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF
CN116179488A (zh) * 2023-03-09 2023-05-30 广东唯泰生物科技有限公司 外周血自然杀伤细胞的体外扩增方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
JP2003521903A (ja) * 2000-01-25 2003-07-22 ハイセック，インコーポレーテッド Ｃｄ８４様ポリペプチドおよびポリヌクレオチドに関する方法と材料
US7029677B2 (en) 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2421056A1 (en) * 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
EP1223218A1 (en) * 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
WO2002077173A2 (en) * 2001-03-22 2002-10-03 Bristol-Myers Squibb Company Polynucleotide encoding a novel immunoglobulin superfamily member, apex4, and variants and splice variants thereof

Also Published As

Publication number Publication date
DE60235985D1 (de) 2010-05-27
EP1406928A1 (en) 2004-04-14
US7138243B2 (en) 2006-11-21
ATE464320T1 (de) 2010-04-15
US20070065875A1 (en) 2007-03-22
WO2003008449A1 (en) 2003-01-30
WO2003008449A8 (en) 2004-02-26
AU2002325333B2 (en) 2008-04-03
US20050159332A1 (en) 2005-07-21
CA2454185A1 (en) 2003-01-30
JP2005507648A (ja) 2005-03-24
EP1406928B1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
US5977303A (en) Mammalian cell surface antigens
Bottino et al. GNTB-A, a novel Sh2d1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus–infected B cells in X-linked lymphoproliferative disease
US20100015153A1 (en) Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
PT726952E (pt) Receptor na superfície de células t activadas: act-4
JP4776845B2 (ja) ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体
US6171803B1 (en) Isolation, characterization, and use of the human β subunit of the high affinity receptor for immunoglobulin E
US20040138126A1 (en) Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
JP2005507648A (ja) ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ
AU2002325333A1 (en) NTB-A, a surface molecule involved in natural killer cells activity
US5998172A (en) Anti-CD6 ligand antibodies
US20080248045A1 (en) Polypeptides having a triggering nk activity and biological applications
AU5670396A (en) Cd6 ligand
US6399065B1 (en) Methods for modulating SLAM-expressing T cells
CA2288307C (en) Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
CA2472111A1 (en) Human mast cell-expressed membrane proteins
KR20210070330A (ko) 혈액 종양의 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법
MXPA97003956A (en) Purified genes that codify antigens of surface of mammali cells, proteins and antibody

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20050714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080730

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090519

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090610

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120619

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130619

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees